Great Bay Bio (GBB), a Hong Kong-based biotechnology firm, announced the completion of a USD 15 million pre-Series B financing round. The funding round was led by Tiger Med’s Tiger Jade Capital, with participation from an unnamed “top life science MNC,” AEF Greater Bay Area Fund (managed by Gobi Partners GBA), and Vectr Ventures, along with other existing institutional investors.
Accelerating Development of AI-Powered Bioprocessing Platforms
GBB stated that the funds will be used to accelerate the development of its AI-powered bioprocessing platforms, including two AI-CMC platforms: AlfaCell for cell line development and AlfaMedX for culture medium library development. These technologies are already being applied to support the development of a range of biologics, including fusion proteins, monoclonal antibodies, and bispecific antibody drugs.
Global Expansion and Strategic Backing
The backing of the unnamed global MNC is expected to help boost the global expansion of GBB’s services in the future. This strategic investment underscores the potential of GBB’s AI-powered bioprocessing platforms to transform the biopharmaceutical industry.-Fineline Info & Tech
